Hypothesis: By 2028, a neuroinflammation-targeted therapy will gain regulatory approval with...
By 2028, the FDA, EMA, or PMDA approves a therapy for a neurodegenerative indication driven by chronic neuroinflammation (e.g., progressive MS, Alzheimer's w...
beach.science